Education
About Us
Working with TipRanks
Follow Us
Labcorp Holdings Inc. (CH:LAB)
:LAB
LAB Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
---
Bulls Say, Bears Say
Bulls Say
EarningsLabcorp Holdings posted solid fourth-quarter results, surpassing expectations with sales of $3.33 billion and adjusted EPS of $3.45.
Financial PerformanceThe company provided 2025 guidance that assumes 7.4% revenue growth at the midpoint, driven by strong diagnostic laboratory revenue growth.
Strategic GrowthMergers and acquisitions remain a strategic focus, contributing significantly to growth and supported by a robust pipeline of potential deals.
Bears Say
Backlog DeclineBacklog decreased ~3.2% due to foreign exchange.
Margin PressureMargins were light on transient items despite solid sales and EPS performance.
Regulatory ChangesThe FDA's plan to phase out animal testing could be a potential overhang for Labcorp Holdings' Early Development unit.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.34% Insiders
27.89%
Mutual Funds
1.02% Other Institutional Investors
46.49% Public Companies and
Individual Investors
LAB FAQ
What was Labcorp Holdings Inc.’s price range in the past 12 months?
Currently, no data Available
What is Labcorp Holdings Inc.’s market cap?
Currently, no data Available
When is Labcorp Holdings Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Labcorp Holdings Inc.’s earnings last quarter?
Labcorp Holdings Inc. released its earnings results on Feb 06, 2025. The company reported $2.833 earnings per share for the quarter, beating the consensus estimate of $2.786 by $0.048.
Is Labcorp Holdings Inc. overvalued?
According to Wall Street analysts Labcorp Holdings Inc.’s price is currently Undervalued.
Does Labcorp Holdings Inc. pay dividends?
Labcorp Holdings Inc. pays a Quarterly dividend of $0.589 which represents an annual dividend yield of 1.33%. See more information on Labcorp Holdings Inc. dividends here
What is Labcorp Holdings Inc.’s EPS estimate?
Labcorp Holdings Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Labcorp Holdings Inc. have?
Currently, no data Available
What happened to Labcorp Holdings Inc.’s price movement after its last earnings report?
Labcorp Holdings Inc. reported an EPS of $2.833 in its last earnings report, beating expectations of $2.786. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Labcorp Holdings Inc.?
Currently, no hedge funds are holding shares in CH:LAB
---
Labcorp Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$225.06 (― Downside)
$225.06 (― Downside)
Blogger Sentiment
Neutral
CH:LAB Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $805.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
16.56%
12-Months-Change
Fundamentals
Return on Equity
9.37%
Trailing 12-Months
Asset Growth
9.89%
Trailing 12-Months
Company Description
Labcorp Holdings Inc.
Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations and accountable care organizations. It offers end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. Laboratory Corporation of America Holdings has a collaboration agreement with Tigerlily Foundation to increase clinical trial diversity for women of color. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.
---
LAB Company Deck
---
LAB Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with strong revenue growth, strategic acquisitions, and innovative test launches. However, there were concerns regarding tariff impacts, regulatory changes, and weather-related disruptions affecting margins.Read More>---
LAB Revenue Breakdown
77.98% Dx
22.47% BLS
---
LAB Stock 12 Month Forecast
Average Price Target
$225.06
---